The skeletal muscle relaxant dantrolene inhibits the release of Ca 2؉ from the sarcoplasmic reticulum during excitation-contraction coupling and suppresses the uncontrolled Ca 2؉ release that underlies the skeletal muscle pharmacogenetic disorder malignant hyperthermia; however, the molecular mechanism by which dantrolene selectively affects skeletal muscle Ca 2؉ regulation remains to be defined. Here we provide evidence of a high-affinity, monophasic inhibition by dantrolene of ryanodine receptor Ca 2؉ channel function in isolated sarcoplasmic reticulum vesicles prepared from malignant hyperthermia-susceptible and normal pig skeletal muscle. In media simulating resting myoplasm, dantrolene increased the half-time for 45 Ca 2؉ release from both malignant hyperthermia and normal vesicles approximately 3. The muscle relaxant dantrolene is a potent and specific inhibitor of skeletal muscle excitation-contraction (E-C) 1 coupling (1). Dantrolene (ϳ10 M) reduces skeletal muscle twitch force by approximately 75% (2) and shifts the sensitivity of contractile activation to higher voltages (3, 4), these effects being attributed to a partial block by dantrolene of Ca 2ϩ release from the sarcoplasmic reticulum (SR) (1, 5, 6) . In contrast to these pronounced effects on skeletal muscle, effects of dantrolene on cardiac muscle contractility are mild or absent (1, 5, 7). Clinically, dantrolene has proven effective in the treatment of malignant hyperthermia (MH), a potentially fatal genetic disorder of skeletal muscle E-C coupling in which exposure to volatile anesthetics triggers uncontrolled SR Ca 2ϩ release, muscle contracture, and accelerated metabolism (8).
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The skeletal muscle relaxant dantrolene inhibits the release of Ca 2؉ from the sarcoplasmic reticulum during excitation-contraction coupling and suppresses the uncontrolled Ca 2؉ release that underlies the skeletal muscle pharmacogenetic disorder malignant hyperthermia; however, the molecular mechanism by which dantrolene selectively affects skeletal muscle Ca 2؉ regulation remains to be defined. Here we provide evidence of a high-affinity, monophasic inhibition by dantrolene of ryanodine receptor Ca 2؉ channel function in isolated sarcoplasmic reticulum vesicles prepared from malignant hyperthermia-susceptible and normal pig skeletal muscle. In media simulating resting myoplasm, dantrolene increased the half-time for 45 Ca 2؉ release from both malignant hyperthermia and normal vesicles approximately 3.5-fold and inhibited sarcoplasmic reticulum vesicle [ 3 
H]ryanodine binding (K i ϳ150 nM for both malignant hyperthermia and normal). Inhibition of vesicle [ 3 H]ryanodine binding by dantrolene was associated with a decrease in the extent of activation by both calmodulin and Ca

2؉
. Dantrolene also inhibited [ 3 H]ryanodine binding to purified skeletal muscle ryanodine receptor protein reconstituted into liposomes. In contrast, cardiac sarcoplasmic reticulum vesicle 45 
Ca
2؉ release and [ 3 H]ryanodine binding were unaffected by dantrolene. Together, these results demonstrate selective effects of dantrolene on skeletal muscle ryanodine receptors that are consistent with the actions of dantrolene in vivo and suggest a mechanism of action in which dantrolene may act directly at the skeletal muscle ryanodine receptor complex to limit its activation by calmodulin and Ca 2؉ . The potential implications of these results for understanding how dantrolene and malignant hyperthermia mutations may affect the voltagedependent activation of Ca 2؉ release in intact skeletal muscle are discussed.
The muscle relaxant dantrolene is a potent and specific inhibitor of skeletal muscle excitation-contraction (E-C) 1 coupling (1) . Dantrolene (ϳ10 M) reduces skeletal muscle twitch force by approximately 75% (2) and shifts the sensitivity of contractile activation to higher voltages (3, 4) , these effects being attributed to a partial block by dantrolene of Ca 2ϩ release from the sarcoplasmic reticulum (SR) (1, 5, 6) . In contrast to these pronounced effects on skeletal muscle, effects of dantrolene on cardiac muscle contractility are mild or absent (1, 5, 7) . Clinically, dantrolene has proven effective in the treatment of malignant hyperthermia (MH), a potentially fatal genetic disorder of skeletal muscle E-C coupling in which exposure to volatile anesthetics triggers uncontrolled SR Ca 2ϩ release, muscle contracture, and accelerated metabolism (8) .
The molecular basis of the action of dantrolene remains undefined but is generally presumed to involve either direct or indirect inhibitory effects on ryanodine receptor (RYR) Ca 2ϩ channels. To date, three RYR isoforms have been identified in mammalian tissues and are termed RYR1, RYR2, and RYR3 (9) . In skeletal muscle, the RYR1 isoform is the major pathway for SR Ca 2ϩ release during E-C coupling, and defects in these channels have been linked to MH susceptibility in pigs and in certain human families (8, 10 (11, 12) . RYR1 channels thus constitute a likely target for the physiologic and therapeutic actions of dantrolene on skeletal muscle Ca 2ϩ regulation. Nonetheless, the precise mechanism by which dantrolene may affect the activation of RYR1 channels has remained unclear. In particular, it is not yet clear how dantrolene may alter RYR1 activation by the physiologic effectors of these channels that have been identified in studies using isolated SR vesicles preparations (13) . In addition, whether the effects of dantrolene may reflect a direct interaction with the RYR1 channel complex itself or rather require dantrolene binding to a separate and as yet unidentified regulatory molecule in the SR membrane remains controversial (12, 14, 15) . Finally, whether the effects of dantrolene may be restricted to the RYR1 channel isoform or may extend to other intracellular Ca 2ϩ release channel isoforms is also in question (16) . The answers to these questions may be important not only in defining the mechanism of action of dantrolene but also in clarifying those aspects of RYR channel regulation that may be specific to skeletal muscle E-C coupling and that may be altered in MH.
In this study, we have examined the effects of dantrolene on the 45 Ca 2ϩ release and [ 3 H]ryanodine binding activity of isolated SR vesicles prepared from MH-susceptible (MHS) and normal pig skeletal muscle. The effects of dantrolene on cardiac SR vesicle 45 Ca 2ϩ release and [ 3 H]ryanodine binding were also examined. Our results demonstrate specific inhibitory effects of dantrolene on the functional activity of skeletal muscle RYR1 channels that are consistent with the effects of dantrolene on E-C coupling in intact muscle and suggest a mechanism of action in which a direct, high-affinity interaction of dantrolene with the RYR1 channel complex may limit the activation of this channel by calmodulin (CaM) and Ca Isolation of SR Vesicles-Skeletal muscle SR vesicles were isolated from the longissimus dorsi muscle of MHS and normal pigs as described previously (17) . Briefly, vesicles obtained by differential ultracentrifugation of a muscle homogenate were extracted with 0.6 M KCl and subsequently fractionated on discontinuous sucrose gradients. The terminal-cisternae-derived (i.e. "heavy") SR vesicles that band at the 36 -40% interface were collected and stored frozen at Ϫ70°C. Cardiac muscle SR vesicles were isolated from porcine ventricular tissue (17) . Following homogenization in 10 mM NaHCO 3 , membranes were extracted in 0.6 M KCl, 20 mM Tris, pH 6.8, and then resuspended in 10% sucrose and stored frozen at Ϫ70°C. All isolation buffers contained a mixture of protease inhibitors (aprotinin, leupeptin, and phenylmethylsulfonyl fluoride). , ϳ100 nM), 1 M CaM, 0.7% methanol, and 10 M dantrolene, as indicated. Ca 2ϩ release was initiated by rapid mixing and stopped at the indicated times (1-10 s using a metronome) by rapid dilution into 12 ml of a release-inhibiting medium (150 mM potassium propionate, 15 mM Pipes, pH 7.0, 10 mM EGTA, 5 mM MgCl 2 , and 20 M ruthenium red), followed immediately by filtration onto 0.45-m Millipore HA membranes. The fraction of total loaded 45 Ca 2ϩ that was not released after 10-s incubations in release media containing Ca 2ϩ ionophore was considered background and was subtracted from all determinations. Estimates of the time required for vesicles to release half of their 45 Ca 2ϩ contents (t 1/2 ) were based on fits to the equation, R ϭ R max ϫ t/(t 1/2 ϩ t), where R is Ca 2ϩ released, R max is the maximal Ca 2ϩ release, and t is time.
[ Purification and Reconstitution of Skeletal Muscle RYR1-RYR1 was isolated on sucrose gradients from Chaps-solubilized skeletal muscle SR essentially as described (18) . For reconstitution of the isolated RYR channel complex into liposomes, gradient fractions containing RYR protein were pooled, concentrated, and diluted (0.1 mg SR protein/ml) into 50 mM NaCl, 50 mM KCl, 20 mM Tris, pH 7.4, 8 mg/ml phosphatidylcholine, 1% Chaps, and dialyzed for 48 h at 4°C against 50 mM NaCl, 50 mM KCl, 20 mM Tris, pH 7.4, 2 mM ␤-mercaptoethanol, 1 mM EGTA, 1 g/ml aprotinin, 1 g/ml leupeptin. Reconstituted RYR1-containing proteoliposomes were collected by centrifugation at 150,000 ϫ g for 30 min and stored frozen at Ϫ70°C. Prior to use, proteoliposome vesicles were slowly thawed, resuspended in 150 mM potassium propionate, 15 mM Pipes, pH 7.0, then sonicated 4 min in a bath sonicator. Proteoliposomes prepared from 2 MHS and 2 normal animals exhibited a mean [ 3 H]ryanodine binding capacity of 154 Ϯ 23 pmol/mg protein. 45 Ca 2ϩ Release-To investigate the effect of dantrolene on the Ca 2ϩ permeability of skeletal muscle SR, 45 Ca 2ϩ release from passively loaded SR vesicles was examined at 36°C in a medium that contained putative physiological effectors of RYR channels (adenine nucleotide, Mg 2ϩ , Ca 2ϩ , and CaM, as described under "Experimental Procedures"). The effects of dantrolene were examined at a concentration (10 M) that approximates therapeutic plasma levels (2) and is known to effectively inhibit the contractility of intact skeletal muscle fiber preparations (1) .
RESULTS
Dantrolene Inhibition of SR Vesicle
In the absence of dantrolene, MHS SR vesicles (Fig. 1A ) exhibited an increased rate of 45 Ca 2ϩ release in comparison to normal SR vesicles (Fig. 1B) . The t 1/2 for 45 Ca 2ϩ release from MHS SR vesicles was thus only one fifth of that from normal SR vesicles (Table I) , consistent with the well-documented increased MHS RYR1 channel activity under a variety of experimental conditions (8) . In the presence of dantrolene, the rate of 45 Ca 2ϩ release from both MHS and normal SR vesicles was decreased (t 1/2 for release increased ϳ3.5-fold for both MHS and normal SR, Table I ). 45 Ca 2ϩ release studies were also performed at 19°C as previous studies have indicated that the effects of dantrolene on intact mammalian fiber preparations are absent below 20°C (4, 19, 20) . At 19°C, the rate of 45 Ca 2ϩ release from MHS SR vesicles was decreased and was similar in the presence and absence of dantrolene ( Fig. 1C and Table I ). These 45 Ca 2ϩ release studies thus indicate that the temperaturedependent inhibitory effect of dantrolene on SR Ca 2ϩ release that has been demonstrated in studies using intact muscle fiber preparations is also evident in studies using isolated SR vesicles.
Dantrolene (Fig. 2) . [ (Fig. 3) . However, inhibition by aminodantrolene required concentrations greater than 3 M, whereas azumolene was a much more potent inhibitor (K i ϭ 84 Ϯ 24 nM). The data in Figs. 2 and 3 thus indicate that dantrolene and its analogues inhibited skeletal muscle RYR activity with distinct potencies (azumolene Ն dantrolene Ͼ Ͼ aminodantrolene). The maximal inhibitory effect of the different analogues was similar, however, and the extent of inhibition was never complete (ϳ40% of activity in the absence of drug). In addition, in media containing dantrolene ( (Fig. 4B) . In contrast, the half-maximally activating CaM concentration for MHS and normal SR vesicles CaM were similar (K a ϳ15 nM, Table II (Fig. 4B) ; however, the K a for CaM activation was unaffected by dantrolene (Table  II) .
Dantrolene Inhibition of [ 3 H]Ryanodine
Binding to Purified RYR1 Reconstituted into Liposomes-To determine if dantrolene inhibition of RYR1 channels in these skeletal muscle SR vesicle preparations may be attributable to a direct action of dantrolene on the RYR1 channel complex, RYR1 protein was isolated from solubilized skeletal muscle SR vesicles and reconstituted into liposomes. Sucrose gradient fractions in which RYR1 was the major protein present were identified by electrophoretic analysis (Fig. 5A) , and RYR1-containing proteoliposomes prepared from these fractions exhibited a greater than 12-fold enrichment of [ 3 H]ryanodine binding capacity in comparison to skeletal muscle SR vesicle preparations ("Experimental Procedures").
As reported previously (18) , following isolation and reconstitution, the MHS RYR1 retained an increased [ 3 H]ryanodine binding activity relative to the normal RYR1 (Fig. 5B) . [ 3 H]Ryanodine binding to both MHS and normal RYR1-containing proteoliposomes was completely inhibited by the RYR channel blocker ruthenium red (10 M). Dantrolene (10 M) also inhibited proteoliposome [ 3 H]ryanodine binding (p Ͻ 0.005 for both MHS and normal), although as in the SR vesicle studies (Fig.  2) , inhibition by dantrolene was incomplete. Furthermore, a lower dantrolene concentration (0.2 M) was approximately half as effective as 10 M dantrolene in inhibiting proteoliposome [ 3 H]ryanodine binding (Fig. 5B) . Thus the isolated, reconstituted skeletal muscle RYR1 protein displayed a sensitivity to inhibition by dantrolene that was similar to that of RYR1 in native SR vesicle preparations (Fig. 2) .
Cardiac SR Vesicle 45 Ca 2ϩ Release and [ 3 H]Ryanodine Binding-To determine if dantrolene inhibition was selective for the skeletal muscle RYR1 channel isoform, the effects of dantrolene on cardiac muscle SR vesicle 45 Ca 2ϩ release and [ 3 H]ryanodine binding were also examined. These experiments were performed in the same media as the corresponding skeletal muscle SR vesicle studies (Figs. 1 and 4 ) and indicated that under these conditions cardiac RYR2 and skeletal RYR1 channels may exhibit previously undescribed differences in their activation by Ca 2ϩ and CaM. Accordingly, Fig. 6A shows that in the presence of 100 nM Ca 2ϩ , the rate of 45 Ca 2ϩ release from cardiac SR vesicles was slow in comparison with that of skeletal muscle SR vesicles ( Fig. 1 and Table I ). Similarly, [ 3 H]ryanodine binding to cardiac SR vesicle was not significantly activated at a Ca 2ϩ concentration of 100 nM (Fig. 6B) . Thus, in comparison with skeletal muscle SR vesicles (Fig. 4A) , the apparent threshold for Ca 2ϩ activation of cardiac SR vesicle [ 3 H]ryanodine binding was higher (Fig. 6B) , and the K a for (Fig. 6 ).
DISCUSSION
Although numerous agents are known to affect the in vitro activity of RYR channels (25) , the effects of dantrolene on these channels are of particular interest for at least two reasons. First, dantrolene is among the most potent and selective modulators of skeletal muscle E-C coupling, and its effects on the voltage-dependent activation of skeletal muscle contraction have been well described (1, 3, 4) . Second, dantrolene is perhaps the only RYR modulator used clinically, and its efficacy in preventing and reversing the pathophysiology of MH in both patients and experimental animals are well established (1, 8) . Thus it is considered that a more complete understanding of the molecular mechanism of dantrolene action may not only provide insights into the in vivo mechanisms controlling RYR1 channels during skeletal muscle E-C coupling but also help to clarify the ways in which these mechanisms may be altered in MH.
Notwithstanding the clear and specific effects of dantrolene on skeletal muscle Ca 2ϩ regulation in patients and in intact muscle fiber preparations, attempts to define its effects on RYR1 channels in more isolated preparations have to date yielded results that are inconsistent and inconclusive. For example, whereas some investigators have reported no effect of dantrolene on SR vesicle 45 Ca 2ϩ release and [ 3 H]ryanodine binding (12, 26, 27) , others have reported inhibitory effects but at dantrolene concentrations that have typically exceeded those required to inhibit the contractility of intact muscle (28 -30) . Most recently, it was reported that RYR1 channels in planar lipid bilayer were either activated or inhibited by dantrolene, depending on the dantrolene concentration (14) . In interpreting these various reports, it therefore remains unclear if the described effects of dantrolene on RYR channels have provided a meaningful reflection of the physiologic and therapeutic actions of the drug in intact muscle. Consequently, the molecular mechanism and locus of dantrolene action have remained undefined. 45 Ca 2ϩ release (A) and [ 3 H]ryanodine binding (B and C) were determined as described under "Experimental Procedures" using conditions equivalent to those used in the corresponding skeletal muscle SR vesicle studies (Figs. 1  and 4) . Data are means Ϯ S.E. from three (A and B) or two (C) cardiac SR vesicle preparations. 2-5) . The SDS-5% polyacrylamide gel was stained with Coomassie Blue. B, [ 3 H]ryanodine binding was determined as described under "Experimental Procedures" at 36°C in media containing 150 mM potassium propionate, 15 mM Pipes, pH 7.0, 3 mM AMPPCP, 2.7 mM MgCl 2 , 1 M CaM, and 100 nM Ca 2ϩ . Data are means Ϯ S.E. of five determinations using RYR1-containing proteoliposomes prepared from two MHS and two normal animals. Asterisks indicate significant inhibition by dantrolene at either the p Ͻ 0.05 (*) or p Ͻ 0.005 (**) level, Student's paired t test.
Dantrolene Inhibition of Skeletal Muscle RYRs Is Consistent with Its actions in Vivo-
In this study, we have further examined the effects of dantrolene on SR vesicle 45 Ca 2ϩ release and [ 3 H]ryanodine binding using media that mimicked physiologic conditions in regard to temperature, ionic composition, and concentrations of RYR effectors. These conditions revealed a selective, monophasic inhibition of skeletal muscle RYR1 channels by dantrolene concentrations in the therapeutic range. Accordingly, inhibition of skeletal muscle SR [ 3 H]ryanodine binding by dantrolene was maximal at 3-30 M, and the concentration dependence of inhibition suggested action at a discrete high-affinity dantrolene site (K i ϳ150 nM) (Fig. 2) . Physiologically active analogues of dantrolene also inhibited skeletal muscle SR vesicle [ 3 H]ryanodine binding (Fig. 3) , and the relative potency of the different analogues reflected their potency in inhibiting skeletal muscle contractility (31) (32) (33) . In addition, dantrolene inhibition of skeletal muscle SR vesicle 45 Ca 2ϩ release (Fig. 1 ) exhibited a temperature dependence that was in agreement with the temperature dependence of dantrolene inhibition demonstrated in muscle fiber preparations from pigs (19) , rats (4), and guinea pigs (20) . Our observations thus demonstrate inhibitory effects of dantrolene on skeletal muscle RYR1 channels that are consistent with the actions of dantrolene on Ca 2ϩ regulation in intact skeletal muscle.
In contrast to these inhibitory effects on the functional activity of skeletal muscle RYR1 channels, dantrolene did not significantly affect cardiac SR vesicle 45 Ca 2ϩ release or [ 3 H]ryanodine binding (Fig. 6 ). These findings are again consistent with the actions of dantrolene in vivo in that any effects of dantrolene on cardiac contractility are mild in comparison with effects on skeletal muscle, require higher concentrations of dantrolene, and can be attributed to effects of dantrolene at sites other than the cardiac SR (1, 5, 7) . Our findings further indicate that the selective effect of dantrolene on skeletal muscle E-C coupling in vivo likely reflects a selective action of dantrolene at skeletal (RYR1) as compared with cardiac (RYR2) isoforms of the Ca 2ϩ release channel. Whether action at RYR1 channels may also account for the effects of dantrolene in certain non-muscle cells (e.g. central neurons, Refs. 16, 34) is not yet clear.
Dantrolene May Act Directly at RYR1 Channels to Limit Activation by CaM and Ca
2ϩ -Parness and co-workers (11, 12) have identified a specific, high-affinity [ 3 H]dantrolene binding site in skeletal muscle SR vesicle preparations and have suggested that this site may reside either on the RYR1 channel itself or on some separate but closely associated regulatory molecule in the SR membrane. The possibility that dantrolene may bind to a receptor distinct from the RYR1 was supported by data which indicated that SR vesicle [ 3 H]dantrolene binding was unaffected by both pharmacological modulators of RYR channels and by the RYR1 mutation associated with porcine MH (11, 12) . In addition, peaks of [ 3 H]dantrolene and [ 3 H]ryanodine binding observed following fractionation of unsolubilized SR vesicles were consistent with the possibility that receptors for dantrolene and ryanodine may be present on overlapping but distinct vesicle populations (12) .
To determine if the inhibitory effects of dantrolene on RYR1 activity that we observed may depend on dantrolene binding to a non-RYR1 receptor, SR vesicles were solubilized and RYR1 protein was isolated on sucrose gradients. Following reconstitution into liposomes, the isolated RYR1 protein displayed a sensitivity to dantrolene comparable with that of RYR1 in native SR (Fig. 5) . This result strongly suggests that the mechanism of dantrolene inhibition does not require dantrolene binding to a receptor that is distinct and easily separable from RYR1 but rather involves a direct interaction of dantrolene with the RYR1 channel complex.
Inhibition of RYR1 channels by dantrolene was associated with clear and pronounced effects on the activation of these channels by CaM. Dantrolene decreased the maximal extent of CaM-activated [ 3 H]ryanodine binding by more than half ( Fig.  4B ) but did not affect the K a for CaM activation (Table II) . This result suggests a noncompetitive inhibition of CaM activation by dantrolene; that is, rather than competing at a CaM activation site on the RYR1 channel, dantrolene may allosterically reduce the fraction of channels that may be activated by CaM. Dantrolene also decreased the maximal extent of Ca 2ϩ -activated [ 3 H]ryanodine binding (Fig. 4A ) and shifted the apparent K a for Ca 2ϩ activation to higher Ca 2ϩ concentrations (Table II) . Notably, the effects of dantrolene on the parameters of RYR1 activation by both CaM and Ca 2ϩ opposed the effects of the MHS RYR1 mutation on channel activation by these effectors. This suggests that dantrolene may inhibit RYR1 channels via a mechanism that selectively counteracts the functional consequences of the MHS Arg 615 3 Cys mutation. Implications for E-C coupling- Fig. 7 incorporates the observed effects of dantrolene on RYR1 channels into a simple model of RYR1 activation during E-C coupling in MHS and normal muscle (36) . The model postulates that RYR1 channels may exist in alternative closed states that differ in their sensitivity to activation by CaM and Ca 2ϩ . Dantrolene is postulated to increase the stability of the insensitive (Closed i ) state, thereby reproducing the observed decrease in the fraction of channels that may be activated by CaM and Ca 2ϩ in the presence of dantrolene (i.e. noncompetitive inhibition, Fig. 4) . Conversely, the MHS Arg 615 3 Cys mutation is postulated to increase the stability of the sensitive (Closed s ) state, thereby reproducing the observed increase in the fraction of MHS channels that may be activated by CaM and Ca 2ϩ ( Fig. 4 ; Refs. [22] [23] .
The model further postulates that transitions between the Closed i and Closed s states may be controlled by depolarization (⌬V) acting through the transverse tubule voltage sensor. In this way, the model reproduces the opposing effects of dantrolene and the Arg 615 3 Cys mutation on the voltage dependence of activation that have been documented in studies using intact muscle fibers (4, 35, 37, 38 (4, 35, 45) . The model suggests that neither dantrolene nor the MHS mutation overides essential control of RYR1 activation by transverse tubule voltage (⌬V) but merely shift the balance of control toward either inactivation or activation, respectively. activation might contribute to a hallmark of skeletal muscle E-C coupling, i.e. rapid activation via a mechanism that operates in the absence of an initial increase in myoplasmic Ca 2ϩ (42) .
Previous work from our laboratory has suggested that, whereas RYR1 channels exhibit changeable Ca 2ϩ activation properties, cardiac RYR2 channels appear to exhibit a more consistent Ca 2ϩ -activable state (43) . In terms of the present model (Fig. 7) , RYR2 channels are thus postulated to exhibit a more stable Closed s state, and the lack of an effect of dantrolene on cardiac SR may be interpreted as a reflection of the increased stability of this state for the RYR2 isoform. Alternatively, the lack of an effect of dantrolene on cardiac SR may reflect the lack of a high-affinity dantrolene binding site on the RYR2 isoform. An additional observation from the present studies was that in contrast to RYR1 channels, RYR2 channels were not activated by physiological CaM (Fig. 6C) . This apparent difference in regulation by CaM may therefore represent an important and previously undescribed functional difference between the RYR1 and RYR2 isoforms. Indeed, if CaM is necessary for RYR1 activation at resting Ca 2ϩ concentrations (above), then the absence of CaM activation of RYR2 would be consistent with a hallmark of cardiac E-C coupling, i.e. activation via a mechanism that is strictly dependent on an initial increase in Ca 2ϩ . In evaluating our model, it will be important to verify differences in the functional interaction of CaM with cardiac and skeletal muscle RYR isoforms. In addition, it will be important to compare the functional consequences of other human MHS RYR1 mutations with those of the Arg 615 3 Cys mutation (44), as the model predicts that rather than altering particular ligand binding sites, MH mutations may affect a global conformational transition in the RYR1 channel that is controlled by transverse tubule depolarization and results in increased channel activation by CaM and Ca 2ϩ . Finally, it will be useful to further define the molecular mechanism of action of RYRisoform-specific modulators of E-C coupling, such as dantrolene.
